Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873827 | 0.89 | MAPT (0.61) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12489677 | 0.82 | MAPT (0.85) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL7902911 | 0.80 | RAB9A (0.76) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL10911272 | 0.76 | KMT2A (0.74) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12490782 | 0.76 | MAPT (1.00) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL21980353 | 0.74 | NPC1 (0.50) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9976069 | 0.73 | NPC1 (0.69) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9146188 | 0.73 | NPC1 (0.69) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL11151582 | 0.72 | MAPT (0.60) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4873172 | 0.71 | XDH (0.63) | MAPTKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1641452-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | Rigel Pharmaceuticals (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1620412-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | MAPT 4317/4885KMT2A 3401/4885MEN1 4601/4885 |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | HAVCR2, PCNA, HCCS | MAPT 4266/4885KMT2A 2974/4885MEN1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.